#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-14	Hallucination-	_
1-2	15-18	and	_
1-3	19-34	speech-specific	_
1-4	35-48	hypercoupling	_
1-5	49-51	in	_
1-6	52-66	frontotemporal	_
1-7	67-75	auditory	_
1-8	76-79	and	_
1-9	80-88	language	_
1-10	89-97	networks	_
1-11	98-100	in	_
1-12	101-114	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-13	115-120	using	_
1-14	121-129	combined	_
1-15	130-140	task-based	_
1-16	141-145	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-17	146-150	data	_
1-18	151-152	:	_
1-19	153-155	an	_
1-20	156-161	fBIRN	_
1-21	162-167	study	_
1-22	168-181	Hypercoupling	_
1-23	182-184	of	_
1-24	185-193	activity	_
1-25	194-196	in	_
1-26	197-223	speech-perception-specific	_
1-27	224-229	brain	_
1-28	230-238	networks	_
1-29	239-242	has	_
1-30	243-247	been	_
1-31	248-256	proposed	_
1-32	257-259	to	_
1-33	260-264	play	_
1-34	265-266	a	_
1-35	267-271	role	_
1-36	272-274	in	_
1-37	275-278	the	_
1-38	279-289	generation	_
1-39	290-292	of	_
1-40	293-308	auditory-verbal	_
1-41	309-323	hallucinations	_
1-42	324-325	(	_
1-43	326-330	AVHs	_
1-44	331-332	)	_
1-45	333-335	in	_
1-46	336-349	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-47	350-351	;	_
1-48	352-359	however	_
1-49	360-361	,	_
1-50	362-364	it	_
1-51	365-367	is	_
1-52	368-375	unclear	_
1-53	376-383	whether	_
1-54	384-388	this	_
1-55	389-402	hypercoupling	_
1-56	403-410	extends	_
1-57	411-413	to	_
1-58	414-424	non-verbal	_
1-59	425-433	auditory	_
1-60	434-444	perception	_
1-61	445-446	.	_

2-1	447-449	We	_
2-2	450-462	investigated	_
2-3	463-467	this	_
2-4	468-470	by	_
2-5	471-480	comparing	_
2-6	481-494	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-7	495-503	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-8	504-508	with	_
2-9	509-512	and	_
2-10	513-520	without	_
2-11	521-525	AVHs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
2-12	526-527	,	_
2-13	528-531	and	_
2-14	532-539	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
2-15	540-548	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
2-16	549-550	,	_
2-17	551-553	on	_
2-18	554-564	task-based	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
2-19	565-575	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-20	576-584	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-21	585-594	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-22	595-602	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-23	603-604	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-24	605-609	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-25	610-611	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-26	612-616	data	_
2-27	617-626	combining	_
2-28	627-633	verbal	_
2-29	634-640	speech	_
2-30	641-651	perception	_
2-31	652-653	(	_
2-32	654-656	SP	_
2-33	657-658	)	_
2-34	659-660	,	_
2-35	661-666	inner	_
2-36	667-673	verbal	_
2-37	674-681	thought	_
2-38	682-692	generation	_
2-39	693-694	(	_
2-40	695-698	VTG	_
2-41	699-700	)	_
2-42	701-702	,	_
2-43	703-706	and	_
2-44	707-717	non-verbal	_
2-45	718-726	auditory	_
2-46	727-734	oddball	_
2-47	735-744	detection	_
2-48	745-746	(	_
2-49	747-749	AO	_
2-50	750-751	)	_
2-51	752-753	.	_

3-1	754-758	Data	_
3-2	759-763	from	_
3-3	764-767	two	_
3-4	768-788	previously-published	_
3-5	789-793	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-6	794-801	studies	_
3-7	802-806	were	_
3-8	807-821	simultaneously	_
3-9	822-830	analyzed	_
3-10	831-836	using	_
3-11	837-842	group	_
3-12	843-854	constrained	_
3-13	855-864	principal	_
3-14	865-874	component	_
3-15	875-883	analysis	_
3-16	884-887	for	_
3-17	888-892	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-18	893-894	(	_
3-19	895-900	group	_
3-20	901-910	fMRI-CPCA	_
3-21	911-912	)	_
3-22	913-914	,	_
3-23	915-920	which	_
3-24	921-928	allowed	_
3-25	929-932	for	_
3-26	933-943	comparison	_
3-27	944-946	of	_
3-28	947-959	task-related	_
3-29	960-970	functional	_
3-30	971-976	brain	_
3-31	977-985	networks	_
3-32	986-992	across	_
3-33	993-999	groups	_
3-34	1000-1003	and	_
3-35	1004-1009	tasks	_
3-36	1010-1015	while	_
3-37	1016-1023	holding	_
3-38	1024-1027	the	_
3-39	1028-1033	brain	_
3-40	1034-1042	networks	_
3-41	1043-1048	under	_
3-42	1049-1054	study	_
3-43	1055-1063	constant	_
3-44	1064-1065	,	_
3-45	1066-1073	leading	_
3-46	1074-1076	to	_
3-47	1077-1090	determination	_
3-48	1091-1093	of	_
3-49	1094-1097	the	_
3-50	1098-1104	degree	_
3-51	1105-1107	to	_
3-52	1108-1113	which	_
3-53	1114-1122	networks	_
3-54	1123-1126	are	_
3-55	1127-1133	common	_
3-56	1134-1136	to	_
3-57	1137-1143	verbal	_
3-58	1144-1147	and	_
3-59	1148-1158	non-verbal	_
3-60	1159-1169	perception	_
3-61	1170-1180	conditions	_
3-62	1181-1182	,	_
3-63	1183-1186	and	_
3-64	1187-1192	which	_
3-65	1193-1197	show	_
3-66	1198-1209	coordinated	_
3-67	1210-1223	hyperactivity	_
3-68	1224-1226	in	_
3-69	1227-1241	hallucinations	_
3-70	1242-1243	.	_

4-1	1244-1249	Three	_
4-2	1250-1260	functional	_
4-3	1261-1266	brain	_
4-4	1267-1275	networks	_
4-5	1276-1283	emerged	_
4-6	1284-1285	:	_
4-7	1286-1287	(	_
4-8	1288-1289	1	_
4-9	1290-1291	)	_
4-10	1292-1306	auditory-motor	_
4-11	1307-1308	,	_
4-12	1309-1310	(	_
4-13	1311-1312	2	_
4-14	1313-1314	)	_
4-15	1315-1323	language	_
4-16	1324-1334	processing	_
4-17	1335-1336	,	_
4-18	1337-1340	and	_
4-19	1341-1342	(	_
4-20	1343-1344	3	_
4-21	1345-1346	)	_
4-22	1347-1359	default-mode	_
4-23	1360-1361	(	_
4-24	1362-1365	DMN	_
4-25	1366-1367	)	_
4-26	1368-1376	networks	_
4-27	1377-1378	.	_

5-1	1379-1388	Combining	_
5-2	1389-1392	the	_
5-3	1393-1395	AO	_
5-4	1396-1399	and	_
5-5	1400-1408	sentence	_
5-6	1409-1414	tasks	_
5-7	1415-1422	allowed	_
5-8	1423-1426	the	_
5-9	1427-1441	auditory-motor	_
5-10	1442-1445	and	_
5-11	1446-1454	language	_
5-12	1455-1463	networks	_
5-13	1464-1466	to	_
5-14	1467-1477	separately	_
5-15	1478-1484	emerge	_
5-16	1485-1486	,	_
5-17	1487-1494	whereas	_
5-18	1495-1499	they	_
5-19	1500-1504	were	_
5-20	1505-1515	aggregated	_
5-21	1516-1520	when	_
5-22	1521-1531	individual	_
5-23	1532-1537	tasks	_
5-24	1538-1542	were	_
5-25	1543-1551	analyzed	_
5-26	1552-1553	.	_

6-1	1554-1557	AVH	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-2	1558-1566	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-3	1567-1573	showed	_
6-4	1574-1581	greater	_
6-5	1582-1593	coordinated	_
6-6	1594-1602	activity	_
6-7	1603-1604	(	_
6-8	1605-1615	deactivity	_
6-9	1616-1619	for	_
6-10	1620-1623	DMN	_
6-11	1624-1631	regions	_
6-12	1632-1633	)	_
6-13	1634-1638	than	_
6-14	1639-1646	non-AVH	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-15	1647-1655	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-16	1656-1662	during	_
6-17	1663-1665	SP	_
6-18	1666-1668	in	_
6-19	1669-1672	all	_
6-20	1673-1681	networks	_
6-21	1682-1683	,	_
6-22	1684-1687	but	_
6-23	1688-1692	this	_
6-24	1693-1696	did	_
6-25	1697-1700	not	_
6-26	1701-1707	extend	_
6-27	1708-1710	to	_
6-28	1711-1714	VTG	_
6-29	1715-1717	or	_
6-30	1718-1720	AO	_
6-31	1721-1722	.	_

7-1	1723-1727	This	_
7-2	1728-1736	suggests	_
7-3	1737-1741	that	_
7-4	1742-1745	the	_
7-5	1746-1759	hypercoupling	_
7-6	1760-1762	in	_
7-7	1763-1766	AVH	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-8	1767-1775	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-9	1776-1778	in	_
7-10	1779-1804	speech-perception-related	_
7-11	1805-1810	brain	_
7-12	1811-1819	networks	_
7-13	1820-1822	is	_
7-14	1823-1831	specific	_
7-15	1832-1834	to	_
7-16	1835-1844	perceived	_
7-17	1845-1851	speech	_
7-18	1852-1853	,	_
7-19	1854-1857	and	_
7-20	1858-1862	does	_
7-21	1863-1866	not	_
7-22	1867-1873	extend	_
7-23	1874-1876	to	_
7-24	1877-1886	perceived	_
7-25	1887-1897	non-speech	_
7-26	1898-1900	or	_
7-27	1901-1906	inner	_
7-28	1907-1913	verbal	_
7-29	1914-1921	thought	_
7-30	1922-1932	generation	_
7-31	1933-1934	.	_

8-1	1935-1942	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
8-2	1943-1955	Participants	_
8-3	1956-1968	Participants	_
8-4	1969-1973	were	_
8-5	1974-1987	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-6	1988-1996	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-7	1997-2000	and	_
8-8	2001-2008	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
8-9	2009-2017	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
8-10	2018-2022	from	_
8-11	2023-2026	two	_
8-12	2027-2037	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-13	2038-2046	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-14	2047-2056	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-15	2057-2064	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-16	2065-2066	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-17	2067-2071	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-18	2072-2073	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-19	2074-2082	datasets	_
8-20	2083-2084	.	_

9-1	2085-2088	The	_
9-2	2089-2094	first	_
9-3	2095-2102	dataset	_
9-4	2103-2112	consisted	_
9-5	2113-2115	of	_
9-6	2116-2118	27	_
9-7	2119-2126	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
9-8	2127-2135	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
9-9	2136-2137	,	_
9-10	2138-2140	11	_
9-11	2141-2148	non-AVH	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
9-12	2149-2150	,	_
9-13	2151-2154	and	_
9-14	2155-2157	12	_
9-15	2158-2161	AVH	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-16	2162-2175	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-17	2176-2184	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-18	2185-2188	who	_
9-19	2189-2198	performed	_
9-20	2199-2200	a	_
9-21	2201-2207	verbal	_
9-22	2208-2216	sentence	_
9-23	2217-2221	task	_
9-24	2222-2231	including	_
9-25	2232-2238	speech	_
9-26	2239-2249	perception	_
9-27	2250-2253	and	_
9-28	2254-2259	inner	_
9-29	2260-2266	verbal	_
9-30	2267-2274	thought	_
9-31	2275-2285	generation	_
9-32	2286-2296	conditions	_
9-33	2297-2298	.	_

10-1	2299-2303	Mean	_
10-2	2304-2311	illness	_
10-3	2312-2320	duration	_
10-4	2321-2324	was	_
10-5	2325-2330	14.05	_
10-6	2331-2336	years	_
10-7	2337-2338	(	_
10-8	2339-2341	SD	_
10-9	2342-2343	=	_
10-10	2344-2349	10.14	_
10-11	2350-2351	)	_
10-12	2352-2353	,	_
10-13	2354-2357	and	_
10-14	2358-2361	all	_
10-15	2362-2365	but	_
10-16	2366-2369	one	_
10-17	2370-2377	patient	_
10-18	2378-2381	was	_
10-19	2382-2391	currently	_
10-20	2392-2398	taking	_
10-21	2399-2412	antipsychotic	_
10-22	2413-2423	medication	_
10-23	2424-2425	.	_

11-1	2426-2434	Nineteen	_
11-2	2435-2443	patients	_
11-3	2444-2448	were	_
11-4	2449-2455	taking	_
11-5	2456-2458	an	_
11-6	2459-2467	atypical	_
11-7	2468-2481	antipsychotic	_
11-8	2482-2483	,	_
11-9	2484-2487	and	_
11-10	2488-2491	two	_
11-11	2492-2496	were	_
11-12	2497-2503	taking	_
11-13	2504-2505	a	_
11-14	2506-2513	typical	_
11-15	2514-2527	antipsychotic	_
11-16	2528-2529	,	_
11-17	2530-2532	as	_
11-18	2533-2538	their	_
11-19	2539-2546	primary	_
11-20	2547-2557	medication	_
11-21	2558-2559	.	_

12-1	2560-2568	Fourteen	_
12-2	2569-2577	patients	_
12-3	2578-2582	were	_
12-4	2583-2587	also	_
12-5	2588-2594	taking	_
12-6	2595-2596	a	_
12-7	2597-2603	second	_
12-8	2604-2617	antipsychotic	_
12-9	2618-2628	medication	_
12-10	2629-2630	(	_
12-11	2631-2632	2	_
12-12	2633-2640	typical	_
12-13	2641-2642	,	_
12-14	2643-2645	12	_
12-15	2646-2654	atypical	_
12-16	2655-2656	)	_
12-17	2657-2658	,	_
12-18	2659-2662	and	_
12-19	2663-2667	four	_
12-20	2668-2672	were	_
12-21	2673-2679	taking	_
12-22	2680-2681	a	_
12-23	2682-2687	third	_
12-24	2688-2696	atypical	_
12-25	2697-2707	medication	_
12-26	2708-2709	(	_
12-27	2710-2711	1	_
12-28	2712-2719	missing	_
12-29	2720-2724	data	_
12-30	2725-2726	)	_
12-31	2727-2728	.	_

13-1	2729-2743	Chlorpromazine	_
13-2	2744-2754	equivalent	_
13-3	2755-2762	dosages	_
13-4	2763-2767	were	_
13-5	2768-2777	available	_
13-6	2778-2781	for	_
13-7	2782-2784	14	_
13-8	2785-2793	patients	_
13-9	2794-2795	:	_
13-10	2796-2800	mean	_
13-11	2801-2802	=	_
13-12	2803-2810	1018.57	_
13-13	2811-2812	;	_
13-14	2813-2815	SD	_
13-15	2816-2817	=	_
13-16	2818-2825	2402.92	_
13-17	2826-2827	.	_

14-1	2828-2836	Symptoms	_
14-2	2837-2841	were	_
14-3	2842-2850	assessed	_
14-4	2851-2856	using	_
14-5	2857-2860	the	_
14-6	2861-2866	Signs	_
14-7	2867-2869	of	_
14-8	2870-2878	Symptoms	_
14-9	2879-2881	of	_
14-10	2882-2891	Psychotic	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder
14-11	2892-2899	Illness	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder
14-12	2900-2901	(	_
14-13	2902-2906	SSPI	_
14-14	2907-2908	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
14-15	2909-2910	,	_
14-16	2911-2916	which	_
14-17	2917-2919	is	_
14-18	2920-2926	scored	_
14-19	2927-2929	on	_
14-20	2930-2931	a	_
14-21	2932-2939	5-point	_
14-22	2940-2945	scale	_
14-23	2946-2959	corresponding	_
14-24	2960-2962	to	_
14-25	2963-2971	severity	_
14-26	2972-2974	of	_
14-27	2975-2989	hallucinations	_
14-28	2990-2991	(	_
14-29	2992-2993	0	_
14-30	2994-2995	=	_
14-31	2996-3002	absent	_
14-32	3003-3004	,	_
14-33	3005-3006	1	_
14-34	3007-3008	=	_
14-35	3009-3014	vague	_
14-36	3015-3027	descriptions	_
14-37	3028-3030	of	_
14-38	3031-3045	hallucinations	_
14-39	3046-3047	,	_
14-40	3048-3049	2	_
14-41	3050-3051	=	_
14-42	3052-3066	hallucinations	_
14-43	3067-3071	that	_
14-44	3072-3075	the	_
14-45	3076-3083	patient	_
14-46	3084-3091	accepts	_
14-47	3092-3094	as	_
14-48	3095-3102	arising	_
14-49	3103-3107	from	_
14-50	3108-3114	within	_
14-51	3115-3122	his/her	_
14-52	3123-3126	own	_
14-53	3127-3131	mind	_
14-54	3132-3133	,	_
14-55	3134-3135	3	_
14-56	3136-3137	=	_
14-57	3138-3146	definite	_
14-58	3147-3161	hallucinations	_
14-59	3162-3171	occurring	_
14-60	3172-3184	occasionally	_
14-61	3185-3186	[	_
14-62	3187-3191	e.g.	_
14-63	3192-3193	,	_
14-64	3194-3195	<	_
14-65	3196-3204	once/day	_
14-66	3205-3206	]	_
14-67	3207-3208	,	_
14-68	3209-3210	4	_
14-69	3211-3212	=	_
14-70	3213-3221	definite	_
14-71	3222-3236	hallucinations	_
14-72	3237-3241	that	_
14-73	3242-3245	are	_
14-74	3246-3254	frequent	_
14-75	3255-3261	and/or	_
14-76	3262-3271	influence	_
14-77	3272-3282	observable	_
14-78	3283-3292	behaviour	_
14-79	3293-3294	)	_
14-80	3295-3296	.	_

15-1	3297-3305	Patients	_
15-2	3306-3313	scoring	_
15-3	3314-3321	greater	_
15-4	3322-3326	than	_
15-5	3327-3328	2	_
15-6	3329-3331	on	_
15-7	3332-3335	the	_
15-8	3336-3350	hallucinations	_
15-9	3351-3355	item	_
15-10	3356-3360	were	_
15-11	3361-3369	included	_
15-12	3370-3372	in	_
15-13	3373-3376	the	_
15-14	3377-3380	AVH	http://maven.renci.org/NeuroBridge/neurobridge#Thing
15-15	3381-3386	group	_
15-16	3387-3388	.	_

16-1	3389-3392	All	_
16-2	3393-3401	patients	_
16-3	3402-3413	experienced	_
16-4	3414-3418	AVHs	_
16-5	3419-3420	(	_
16-6	3421-3425	i.e.	_
16-7	3426-3427	,	_
16-8	3428-3434	voices	_
16-9	3435-3436	)	_
16-10	3437-3438	,	_
16-11	3439-3445	though	_
16-12	3446-3449	two	_
16-13	3450-3454	also	_
16-14	3455-3466	experienced	_
16-15	3467-3472	other	_
16-16	3473-3481	auditory	_
16-17	3482-3496	hallucinations	_
16-18	3497-3498	,	_
16-19	3499-3503	such	_
16-20	3504-3506	as	_
16-21	3507-3515	auditory	_
16-22	3516-3527	distortions	_
16-23	3528-3529	,	_
16-24	3530-3536	simple	_
16-25	3537-3543	noises	_
16-26	3544-3545	,	_
16-27	3546-3549	and	_
16-28	3550-3555	music	_
16-29	3556-3557	.	_

17-1	3558-3561	Six	_
17-2	3562-3570	patients	_
17-3	3571-3575	also	_
17-4	3576-3587	experienced	_
17-5	3588-3598	multimodal	_
17-6	3599-3613	hallucinations	_
17-7	3614-3615	(	_
17-8	3616-3617	6	_
17-9	3618-3625	tactile	_
17-10	3626-3627	,	_
17-11	3628-3629	3	_
17-12	3630-3636	visual	_
17-13	3637-3638	,	_
17-14	3639-3640	1	_
17-15	3641-3650	olfactory	_
17-16	3651-3652	)	_
17-17	3653-3654	.	_

18-1	3655-3658	All	_
18-2	3659-3671	participants	_
18-3	3672-3676	were	_
18-4	3677-3685	screened	_
18-5	3686-3689	for	_
18-6	3690-3693	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
18-7	3694-3707	compatibility	_
18-8	3708-3711	and	_
18-9	3712-3716	gave	_
18-10	3717-3724	written	_
18-11	3725-3733	informed	_
18-12	3734-3741	consent	_
18-13	3742-3747	prior	_
18-14	3748-3750	to	_
18-15	3751-3764	participation	_
18-16	3765-3766	.	_

19-1	3767-3779	Experimental	_
19-2	3780-3790	procedures	_
19-3	3791-3795	were	_
19-4	3796-3804	approved	_
19-5	3805-3807	as	_
19-6	3808-3812	part	_
19-7	3813-3815	of	_
19-8	3816-3817	a	_
19-9	3818-3824	larger	_
19-10	3825-3830	study	_
19-11	3831-3833	by	_
19-12	3834-3837	the	_
19-13	3838-3848	University	_
19-14	3849-3851	of	_
19-15	3852-3859	British	_
19-16	3860-3868	Columbia	_
19-17	3869-3877	clinical	_
19-18	3878-3886	research	_
19-19	3887-3893	ethics	_
19-20	3894-3899	board	_
19-21	3900-3901	.	_

20-1	3902-3905	The	_
20-2	3906-3912	second	_
20-3	3913-3920	dataset	_
20-4	3921-3924	was	_
20-5	3925-3933	acquired	_
20-6	3934-3938	from	_
20-7	3939-3942	the	_
20-8	3943-3951	publicly	_
20-9	3952-3961	available	_
20-10	3962-3967	fBIRN	_
20-11	3968-3973	phase	_
20-12	3974-3976	II	_
20-13	3977-3986	multisite	_
20-14	3987-3992	study	_
20-15	3993-3994	,	_
20-16	3995-4000	which	_
20-17	4001-4009	consists	_
20-18	4010-4012	of	_
20-19	4013-4017	data	_
20-20	4018-4027	collected	_
20-21	4028-4030	at	_
20-22	4031-4034	six	_
20-23	4035-4040	sites	_
20-24	4041-4047	across	_
20-25	4048-4051	the	_
20-26	4052-4058	United	_
20-27	4059-4065	States	_
20-28	4066-4068	of	_
20-29	4069-4076	America	_
20-30	4077-4078	:	_
20-31	4079-4087	Duke/UNC	_
20-32	4088-4089	,	_
20-33	4090-4097	Brigham	_
20-34	4098-4101	and	_
20-35	4102-4107	Women	_
20-36	4108-4109	’	_
20-37	4110-4111	s	_
20-38	4112-4120	Hospital	_
20-39	4121-4122	,	_
20-40	4123-4136	Massachusetts	_
20-41	4137-4144	General	_
20-42	4145-4153	Hospital	_
20-43	4154-4155	,	_
20-44	4156-4166	University	_
20-45	4167-4169	of	_
20-46	4170-4180	California	_
20-47	4181-4182	–	_
20-48	4183-4189	Irvine	_
20-49	4190-4191	,	_
20-50	4192-4202	University	_
20-51	4203-4205	of	_
20-52	4206-4209	New	_
20-53	4210-4216	Mexico	_
20-54	4217-4218	,	_
20-55	4219-4222	and	_
20-56	4223-4227	Yale	_
20-57	4228-4229	.	_

21-1	4230-4234	Data	_
21-2	4235-4239	were	_
21-3	4240-4250	downloaded	_
21-4	4251-4255	from	_
21-5	4256-4259	the	_
21-6	4260-4265	fBIRN	_
21-7	4266-4270	Data	_
21-8	4271-4281	Repository	_
21-9	4282-4283	,	_
21-10	4284-4291	Project	_
21-11	4292-4301	Accession	_
21-12	4302-4308	Number	_
21-13	4309-4323	2007-BDR-6UHZ1	_
21-14	4324-4325	.	_

22-1	4326-4329	The	_
22-2	4330-4348	quality-controlled	_
22-3	4349-4353	data	_
22-4	4354-4357	set	_
22-5	4358-4359	(	_
22-6	4360-4363	see	_
22-7	4364-4365	)	_
22-8	4366-4374	included	_
22-9	4375-4377	50	_
22-10	4378-4385	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
22-11	4386-4394	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
22-12	4395-4396	,	_
22-13	4397-4399	23	_
22-14	4400-4407	non-AVH	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
22-15	4408-4409	,	_
22-16	4410-4413	and	_
22-17	4414-4416	35	_
22-18	4417-4420	AVH	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
22-19	4421-4429	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
22-20	4430-4439	diagnosed	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
22-21	4440-4444	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
22-22	4445-4458	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
22-23	4459-4461	or	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
22-24	4462-4477	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
22-25	4478-4486	disorder	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
22-26	4487-4490	who	_
22-27	4491-4500	completed	_
22-28	4501-4503	an	_
22-29	4504-4512	auditory	_
22-30	4513-4520	oddball	_
22-31	4521-4525	task	_
22-32	4526-4527	.	_

23-1	4528-4536	Patients	_
23-2	4537-4538	’	_
23-3	4539-4547	symptoms	_
23-4	4548-4552	were	_
23-5	4553-4561	assessed	_
23-6	4562-4567	using	_
23-7	4568-4571	the	_
23-8	4572-4577	Scale	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
23-9	4578-4581	for	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
23-10	4582-4585	the	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
23-11	4586-4596	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
23-12	4597-4599	of	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
23-13	4600-4608	Positive	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
23-14	4609-4617	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
23-15	4618-4619	(	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
23-16	4620-4624	SAPS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
23-17	4625-4626	)	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
23-18	4627-4628	,	_
23-19	4629-4634	which	_
23-20	4635-4637	is	_
23-21	4638-4644	scored	_
23-22	4645-4647	on	_
23-23	4648-4649	a	_
23-24	4650-4659	six-point	_
23-25	4660-4665	scale	_
23-26	4666-4670	from	_
23-27	4671-4672	0	_
23-28	4673-4675	to	_
23-29	4676-4677	5	_
23-30	4678-4680	in	_
23-31	4681-4691	increasing	_
23-32	4692-4700	severity	_
23-33	4701-4702	:	_
23-34	4703-4704	0	_
23-35	4705-4706	=	_
23-36	4707-4711	none	_
23-37	4712-4713	;	_
23-38	4714-4715	1	_
23-39	4716-4717	=	_
23-40	4718-4730	questionable	_
23-41	4731-4732	;	_
23-42	4733-4734	2	_
23-43	4735-4736	=	_
23-44	4737-4741	mild	_
23-45	4742-4743	(	_
23-46	4744-4750	noises	_
23-47	4751-4753	or	_
23-48	4754-4760	single	_
23-49	4761-4766	words	_
23-50	4767-4768	,	_
23-51	4769-4774	which	_
23-52	4775-4779	only	_
23-53	4780-4786	appear	_
23-54	4787-4799	occasionally	_
23-55	4800-4801	)	_
23-56	4802-4803	;	_
23-57	4804-4805	3	_
23-58	4806-4807	=	_
23-59	4808-4816	moderate	_
23-60	4817-4818	(	_
23-61	4819-4824	clear	_
23-62	4825-4833	evidence	_
23-63	4834-4836	of	_
23-64	4837-4843	voices	_
23-65	4844-4853	occurring	_
23-66	4854-4856	at	_
23-67	4857-4862	least	_
23-68	4863-4869	weekly	_
23-69	4870-4871	)	_
23-70	4872-4873	;	_
23-71	4874-4875	4	_
23-72	4876-4877	=	_
23-73	4878-4884	marked	_
23-74	4885-4886	(	_
23-75	4887-4892	clear	_
23-76	4893-4901	evidence	_
23-77	4902-4904	of	_
23-78	4905-4911	voices	_
23-79	4912-4921	occurring	_
23-80	4922-4928	almost	_
23-81	4929-4934	daily	_
23-82	4935-4936	)	_
23-83	4937-4938	;	_
23-84	4939-4940	5	_
23-85	4941-4942	=	_
23-86	4943-4949	severe	_
23-87	4950-4951	(	_
23-88	4952-4958	voices	_
23-89	4959-4964	occur	_
23-90	4965-4970	often	_
23-91	4971-4976	daily	_
23-92	4977-4978	)	_
23-93	4979-4980	.	_

24-1	4981-4983	As	_
24-2	4984-4988	with	_
24-3	4989-4992	the	_
24-4	4993-5001	sentence	_
24-5	5002-5006	task	_
24-6	5007-5013	sample	_
24-7	5014-5015	,	_
24-8	5016-5024	patients	_
24-9	5025-5032	scoring	_
24-10	5033-5040	greater	_
24-11	5041-5045	than	_
24-12	5046-5047	2	_
24-13	5048-5050	on	_
24-14	5051-5054	the	_
24-15	5055-5069	hallucinations	_
24-16	5070-5074	item	_
24-17	5075-5079	were	_
24-18	5080-5088	included	_
24-19	5089-5091	in	_
24-20	5092-5095	the	_
24-21	5096-5099	AVH	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
24-22	5100-5105	group	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
24-23	5106-5107	.	_

25-1	5108-5119	Observation	_
25-2	5120-5122	of	_
25-3	5123-5129	scores	_
25-4	5130-5132	on	_
25-5	5133-5136	the	_
25-6	5137-5141	SAPS	_
25-7	5142-5147	items	_
25-8	5148-5154	Voices	_
25-9	5155-5165	Commenting	_
25-10	5166-5169	and	_
25-11	5170-5176	Voices	_
25-12	5177-5187	Conversing	_
25-13	5188-5197	confirmed	_
25-14	5198-5202	that	_
25-15	5203-5207	most	_
25-16	5208-5221	hallucinating	_
25-17	5222-5230	patients	_
25-18	5231-5242	experienced	_
25-19	5243-5247	AVHs	_
25-20	5248-5249	;	_
25-21	5250-5257	however	_
25-22	5258-5259	,	_
25-23	5260-5263	the	_
25-24	5264-5272	presence	_
25-25	5273-5275	of	_
25-26	5276-5280	AVHs	_
25-27	5281-5286	could	_
25-28	5287-5290	not	_
25-29	5291-5293	be	_
25-30	5294-5303	confirmed	_
25-31	5304-5306	in	_
25-32	5307-5312	eight	_
25-33	5313-5321	patients	_
25-34	5322-5325	who	_
25-35	5326-5334	reported	_
25-36	5335-5343	auditory	_
25-37	5344-5358	hallucinations	_
25-38	5359-5360	,	_
25-39	5361-5363	as	_
25-40	5364-5367	the	_
25-41	5368-5380	AVH-specific	_
25-42	5381-5386	items	_
25-43	5387-5391	were	_
25-44	5392-5395	not	_
25-45	5396-5404	endorsed	_
25-46	5405-5407	or	_
25-47	5408-5412	were	_
25-48	5413-5419	scored	_
25-49	5420-5425	below	_
25-50	5426-5429	the	_
25-51	5430-5434	same	_
25-52	5435-5442	cut-off	_
25-53	5443-5448	value	_
25-54	5449-5451	of	_
25-55	5452-5453	2	_
25-56	5454-5455	.	_

26-1	5456-5464	Nineteen	_
26-2	5465-5473	patients	_
26-3	5474-5478	also	_
26-4	5479-5487	reported	_
26-5	5488-5498	multimodal	_
26-6	5499-5513	hallucinations	_
26-7	5514-5515	(	_
26-8	5516-5518	10	_
26-9	5519-5534	somatic-tactile	_
26-10	5535-5536	,	_
26-11	5537-5538	6	_
26-12	5539-5548	olfactory	_
26-13	5549-5550	,	_
26-14	5551-5553	13	_
26-15	5554-5560	visual	_
26-16	5561-5562	)	_
26-17	5563-5564	.	_

27-1	5565-5568	All	_
27-2	5569-5577	patients	_
27-3	5578-5582	were	_
27-4	5583-5589	stable	_
27-5	5590-5593	and	_
27-6	5594-5597	had	_
27-7	5598-5600	no	_
27-8	5601-5608	changes	_
27-9	5609-5611	in	_
27-10	5612-5617	their	_
27-11	5618-5629	medications	_
27-12	5630-5632	in	_
27-13	5633-5636	the	_
27-14	5637-5640	two	_
27-15	5641-5647	months	_
27-16	5648-5653	prior	_
27-17	5654-5656	to	_
27-18	5657-5664	testing	_
27-19	5665-5666	;	_
27-20	5667-5674	however	_
27-21	5675-5676	,	_
27-22	5677-5687	additional	_
27-23	5688-5699	information	_
27-24	5700-5709	regarding	_
27-25	5710-5720	medication	_
27-26	5721-5724	and	_
27-27	5725-5732	illness	_
27-28	5733-5740	history	_
27-29	5741-5744	was	_
27-30	5745-5748	not	_
27-31	5749-5758	available	_
27-32	5759-5760	,	_
27-33	5761-5766	which	_
27-34	5767-5776	precluded	_
27-35	5777-5779	us	_
27-36	5780-5784	from	_
27-37	5785-5794	comparing	_
27-38	5795-5798	the	_
27-39	5799-5802	two	_
27-40	5803-5810	samples	_
27-41	5811-5813	on	_
27-42	5814-5819	these	_
27-43	5820-5828	measures	_
27-44	5829-5830	.	_

28-1	5831-5834	All	_
28-2	5835-5840	fBIRN	http://maven.renci.org/NeuroBridge/neurobridge#BirchwoodSocialFunctioningScale
28-3	5841-5846	sites	_
28-4	5847-5855	received	_
28-5	5856-5861	local	_
28-6	5862-5875	Institutional	_
28-7	5876-5882	Review	_
28-8	5883-5888	Board	_
28-9	5889-5897	approval	_
28-10	5898-5899	.	_

29-1	5900-5905	Table	_
29-2	5906-5907	1	_
29-3	5908-5913	shows	_
29-4	5914-5925	demographic	_
29-5	5926-5937	information	_
29-6	5938-5941	for	_
29-7	5942-5946	each	_
29-8	5947-5952	group	_
29-9	5953-5954	,	_
29-10	5955-5958	for	_
29-11	5959-5962	the	_
29-12	5963-5971	auditory	_
29-13	5972-5979	oddball	_
29-14	5980-5983	and	_
29-15	5984-5992	sentence	_
29-16	5993-5998	tasks	_
29-17	5999-6009	separately	_
29-18	6010-6011	.	_

30-1	6012-6017	There	_
30-2	6018-6022	were	_
30-3	6023-6025	no	_
30-4	6026-6037	significant	_
30-5	6038-6049	differences	_
30-6	6050-6057	between	_
30-7	6058-6064	groups	_
30-8	6065-6067	on	_
30-9	6068-6071	age	_
30-10	6072-6073	,	_
30-11	6074-6080	gender	_
30-12	6081-6083	or	_
30-13	6084-6094	handedness	_
30-14	6095-6098	for	_
30-15	6099-6105	either	_
30-16	6106-6110	task	_
30-17	6111-6112	.	_

31-1	6113-6125	Experimental	_
31-2	6126-6132	Design	_
31-3	6133-6141	Sentence	_
31-4	6142-6146	Task	_
31-5	6147-6159	Participants	_
31-6	6160-6164	were	_
31-7	6165-6174	presented	_
31-8	6175-6179	with	_
31-9	6180-6181	a	_
31-10	6182-6186	noun	_
31-11	6187-6188	(	_
31-12	6189-6195	object	_
31-13	6196-6197	)	_
31-14	6198-6201	and	_
31-15	6202-6205	its	_
31-16	6206-6219	corresponding	_
31-17	6220-6225	image	_
31-18	6226-6227	(	_
31-19	6228-6232	e.g.	_
31-20	6233-6234	,	_
31-21	6235-6240	Table	_
31-22	6241-6242	)	_
31-23	6243-6246	and	_
31-24	6247-6257	instructed	_
31-25	6258-6260	to	_
31-26	6261-6267	either	_
31-27	6268-6274	listen	_
31-28	6275-6277	to	_
31-29	6278-6279	(	_
31-30	6280-6286	speech	_
31-31	6287-6297	perception	_
31-32	6298-6307	condition	_
31-33	6308-6309	;	_
31-34	6310-6312	SP	_
31-35	6313-6314	)	_
31-36	6315-6317	or	_
31-37	6318-6326	mentally	_
31-38	6327-6335	generate	_
31-39	6336-6337	(	_
31-40	6338-6343	inner	_
31-41	6344-6350	verbal	_
31-42	6351-6358	thought	_
31-43	6359-6369	generation	_
31-44	6370-6379	condition	_
31-45	6380-6381	;	_
31-46	6382-6385	VTG	_
31-47	6386-6387	)	_
31-48	6388-6389	a	_
31-49	6390-6396	simple	_
31-50	6397-6407	definition	_
31-51	6408-6410	of	_
31-52	6411-6414	the	_
31-53	6415-6419	word	_
31-54	6420-6421	(	_
31-55	6422-6426	e.g.	_
31-56	6427-6428	,	_
31-57	6429-6430	“	_
31-58	6431-6440	Something	_
31-59	6441-6444	you	_
31-60	6445-6448	eat	_
31-61	6449-6455	dinner	_
31-62	6456-6458	on	_
31-63	6459-6460	”	_
31-64	6461-6462	;	_
31-65	6463-6466	see	_
31-66	6467-6474	Figures	_
31-67	6475-6477	1A	_
31-68	6478-6481	and	_
31-69	6482-6484	1B	_
31-70	6485-6486	,	_
31-71	6487-6499	respectively	_
31-72	6500-6501	)	_
31-73	6502-6503	.	_

32-1	6504-6507	The	_
32-2	6508-6510	SP	_
32-3	6511-6514	and	_
32-4	6515-6518	VTG	_
32-5	6519-6529	conditions	_
32-6	6530-6534	were	_
32-7	6535-6544	presented	_
32-8	6545-6547	in	_
32-9	6548-6554	blocks	_
32-10	6555-6565	consisting	_
32-11	6566-6568	of	_
32-12	6569-6571	15	_
32-13	6572-6578	trials	_
32-14	6579-6583	each	_
32-15	6584-6585	(	_
32-16	6586-6588	30	_
32-17	6589-6595	trials	_
32-18	6596-6601	total	_
32-19	6602-6605	for	_
32-20	6606-6610	each	_
32-21	6611-6620	condition	_
32-22	6621-6627	across	_
32-23	6628-6631	two	_
32-24	6632-6636	runs	_
32-25	6637-6638	)	_
32-26	6639-6640	,	_
32-27	6641-6645	with	_
32-28	6646-6648	an	_
32-29	6649-6660	inter-trial	_
32-30	6661-6669	interval	_
32-31	6670-6671	(	_
32-32	6672-6675	ITI	_
32-33	6676-6677	)	_
32-34	6678-6685	between	_
32-35	6686-6693	stimuli	_
32-36	6694-6695	,	_
32-37	6696-6699	and	_
32-38	6700-6701	a	_
32-39	6702-6705	60s	_
32-40	6706-6710	rest	_
32-41	6711-6716	break	_
32-42	6717-6724	between	_
32-43	6725-6728	the	_
32-44	6729-6732	two	_
32-45	6733-6743	conditions	_
32-46	6744-6745	.	_

33-1	6746-6749	The	_
33-2	6750-6753	ITI	_
33-3	6754-6757	was	_
33-4	6758-6769	exponential	_
33-5	6770-6772	to	_
33-6	6773-6781	optimize	_
33-7	6782-6795	deconvolution	_
33-8	6796-6798	of	_
33-9	6799-6802	the	_
33-10	6803-6808	blood	_
33-11	6809-6820	oxygenation	_
33-12	6821-6826	level	_
33-13	6827-6836	dependent	_
33-14	6837-6838	(	_
33-15	6839-6843	BOLD	_
33-16	6844-6845	)	_
33-17	6846-6852	signal	_
33-18	6853-6854	,	_
33-19	6855-6858	and	_
33-20	6859-6865	lasted	_
33-21	6866-6870	from	_
33-22	6871-6872	2	_
33-23	6873-6875	to	_
33-24	6876-6879	20s	_
33-25	6880-6881	(	_
33-26	6882-6886	mean	_
33-27	6887-6888	=	_
33-28	6889-6894	4.46s	_
33-29	6895-6896	)	_
33-30	6897-6898	.	_

34-1	6899-6906	Stimuli	_
34-2	6907-6911	were	_
34-3	6912-6920	randomly	_
34-4	6921-6929	assigned	_
34-5	6930-6932	to	_
34-6	6933-6937	each	_
34-7	6938-6947	condition	_
34-8	6948-6951	for	_
34-9	6952-6956	each	_
34-10	6957-6968	participant	_
34-11	6969-6979	separately	_
34-12	6980-6981	.	_

35-1	6982-6985	The	_
35-2	6986-6996	conditions	_
35-3	6997-7001	were	_
35-4	7002-7006	cued	_
35-5	7007-7011	with	_
35-6	7012-7015	the	_
35-7	7016-7021	words	_
35-8	7022-7023	“	_
35-9	7024-7031	listen…	_
35-10	7032-7033	”	_
35-11	7034-7037	and	_
35-12	7038-7039	“	_
35-13	7040-7049	something	_
35-14	7050-7054	you…	_
35-15	7055-7056	”	_
35-16	7057-7066	presented	_
35-17	7067-7072	under	_
35-18	7073-7076	the	_
35-19	7077-7083	images	_
35-20	7084-7086	in	_
35-21	7087-7090	the	_
35-22	7091-7093	SP	_
35-23	7094-7097	and	_
35-24	7098-7101	VTG	_
35-25	7102-7112	conditions	_
35-26	7113-7114	,	_
35-27	7115-7127	respectively	_
35-28	7128-7129	,	_
35-29	7130-7132	in	_
35-30	7133-7138	order	_
35-31	7139-7141	to	_
35-32	7142-7148	ensure	_
35-33	7149-7153	that	_
35-34	7154-7156	at	_
35-35	7157-7162	least	_
35-36	7163-7167	some	_
35-37	7168-7173	words	_
35-38	7174-7178	were	_
35-39	7179-7187	mentally	_
35-40	7188-7197	generated	_
35-41	7198-7200	on	_
35-42	7201-7206	every	_
35-43	7207-7212	trial	_
35-44	7213-7214	,	_
35-45	7215-7218	and	_
35-46	7219-7221	to	_
35-47	7222-7230	minimize	_
35-48	7231-7234	any	_
35-49	7235-7251	interpretational	_
35-50	7252-7261	confounds	_
35-51	7262-7269	between	_
35-52	7270-7280	conditions	_
35-53	7281-7282	.	_

36-1	7283-7292	Following	_
36-2	7293-7296	the	_
36-3	7297-7307	experiment	_
36-4	7308-7309	,	_
36-5	7310-7322	participants	_
36-6	7323-7327	were	_
36-7	7328-7333	asked	_
36-8	7334-7341	whether	_
36-9	7342-7344	or	_
36-10	7345-7348	not	_
36-11	7349-7353	they	_
36-12	7354-7365	experienced	_
36-13	7366-7380	hallucinations	_
36-14	7381-7387	during	_
36-15	7388-7391	the	_
36-16	7392-7400	scanning	_
36-17	7401-7408	session	_
36-18	7409-7410	.	_

37-1	7411-7414	One	_
37-2	7415-7422	patient	_
37-3	7423-7431	reported	_
37-4	7432-7438	active	_
37-5	7439-7443	AVHs	_
37-6	7444-7450	during	_
37-7	7451-7454	the	_
37-8	7455-7461	speech	_
37-9	7462-7472	perception	_
37-10	7473-7479	trials	_
37-11	7480-7481	,	_
37-12	7482-7485	and	_
37-13	7486-7489	one	_
37-14	7490-7497	patient	_
37-15	7498-7506	reported	_
37-16	7507-7514	tactile	_
37-17	7515-7529	hallucinations	_
37-18	7530-7536	during	_
37-19	7537-7540	the	_
37-20	7541-7548	thought	_
37-21	7549-7559	generation	_
37-22	7560-7566	trials	_
37-23	7567-7568	(	_
37-24	7569-7573	data	_
37-25	7574-7578	were	_
37-26	7579-7586	missing	_
37-27	7587-7590	for	_
37-28	7591-7594	two	_
37-29	7595-7603	subjects	_
37-30	7604-7605	)	_
37-31	7606-7607	.	_

38-1	7608-7613	fBIRN	http://maven.renci.org/NeuroBridge/neurobridge#BirchwoodSocialFunctioningScale
38-2	7614-7622	Auditory	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryOddballTask
38-3	7623-7630	Oddball	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryOddballTask
38-4	7631-7635	Task	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryOddballTask
38-5	7636-7639	The	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryOddballTask
38-6	7640-7648	two-tone	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask
38-7	7649-7651	AO	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask
38-8	7652-7656	task	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask
38-9	7657-7658	(	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask
38-10	7659-7665	Figure	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask
38-11	7666-7668	1C	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask
38-12	7669-7670	)	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask
38-13	7671-7679	involved	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask
38-14	7680-7689	listening	_
38-15	7690-7692	to	_
38-16	7693-7694	a	_
38-17	7695-7701	series	_
38-18	7702-7704	of	_
38-19	7705-7710	tones	_
38-20	7711-7714	and	_
38-21	7715-7725	indicating	_
38-22	7726-7730	with	_
38-23	7731-7732	a	_
38-24	7733-7739	button	_
38-25	7740-7745	press	_
38-26	7746-7750	when	_
38-27	7751-7752	a	_
38-28	7753-7759	target	_
38-29	7760-7764	tone	_
38-30	7765-7766	(	_
38-31	7767-7771	i.e.	_
38-32	7772-7773	,	_
38-33	7774-7775	a	_
38-34	7776-7780	tone	_
38-35	7781-7790	deviating	_
38-36	7791-7793	in	_
38-37	7794-7803	frequency	_
38-38	7804-7805	)	_
38-39	7806-7809	was	_
38-40	7810-7819	presented	_
38-41	7820-7821	.	_

39-1	7822-7826	Four	_
39-2	7827-7831	runs	_
39-3	7832-7834	of	_
39-4	7835-7838	the	_
39-5	7839-7847	auditory	_
39-6	7848-7855	oddball	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryOddballTask
39-7	7856-7860	task	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryOddballTask
39-8	7861-7865	were	_
39-9	7866-7875	completed	_
39-10	7876-7878	in	_
39-11	7879-7883	each	_
39-12	7884-7886	of	_
39-13	7887-7890	two	_
39-14	7891-7899	sessions	_
39-15	7900-7901	,	_
39-16	7902-7909	leading	_
39-17	7910-7912	to	_
39-18	7913-7914	a	_
39-19	7915-7920	total	_
39-20	7921-7923	of	_
39-21	7924-7929	eight	_
39-22	7930-7934	runs	_
39-23	7935-7938	per	_
39-24	7939-7946	subject	_
39-25	7947-7951	that	_
39-26	7952-7956	each	_
39-27	7957-7963	lasted	_
39-28	7964-7968	280s	_
39-29	7969-7970	.	_

40-1	7971-7975	Each	_
40-2	7976-7979	run	_
40-3	7980-7985	began	_
40-4	7986-7990	with	_
40-5	7991-7994	15s	_
40-6	7995-7997	of	_
40-7	7998-8005	silence	_
40-8	8006-8007	,	_
40-9	8008-8016	followed	_
40-10	8017-8019	by	_
40-11	8020-8021	a	_
40-12	8022-8028	series	_
40-13	8029-8031	of	_
40-14	8032-8037	tones	_
40-15	8038-8045	lasting	_
40-16	8046-8051	100ms	_
40-17	8052-8056	each	_
40-18	8057-8058	,	_
40-19	8059-8063	with	_
40-20	8064-8069	500ms	_
40-21	8070-8083	interstimulus	_
40-22	8084-8093	intervals	_
40-23	8094-8101	between	_
40-24	8102-8106	them	_
40-25	8107-8108	;	_
40-26	8109-8110	a	_
40-27	8111-8114	15s	_
40-28	8115-8121	period	_
40-29	8122-8124	of	_
40-30	8125-8132	silence	_
40-31	8133-8142	indicated	_
40-32	8143-8146	the	_
40-33	8147-8150	end	_
40-34	8151-8153	of	_
40-35	8154-8158	each	_
40-36	8159-8162	run	_
40-37	8163-8164	.	_

41-1	8165-8168	The	_
41-2	8169-8177	majority	_
41-3	8178-8180	of	_
41-4	8181-8184	the	_
41-5	8185-8190	tones	_
41-6	8191-8192	(	_
41-7	8193-8201	standard	_
41-8	8202-8207	tones	_
41-9	8208-8209	;	_
41-10	8210-8212	95	_
41-11	8213-8214	%	_
41-12	8215-8225	occurrence	_
41-13	8226-8227	)	_
41-14	8228-8232	were	_
41-15	8233-8242	presented	_
41-16	8243-8245	at	_
41-17	8246-8247	a	_
41-18	8248-8257	frequency	_
41-19	8258-8260	of	_
41-20	8261-8267	1000Hz	_
41-21	8268-8271	and	_
41-22	8272-8275	the	_
41-23	8276-8285	remaining	_
41-24	8286-8291	tones	_
41-25	8292-8293	(	_
41-26	8294-8300	target	_
41-27	8301-8306	tones	_
41-28	8307-8308	;	_
41-29	8309-8310	5	_
41-30	8311-8312	%	_
41-31	8313-8323	occurrence	_
41-32	8324-8325	)	_
41-33	8326-8330	were	_
41-34	8331-8340	presented	_
41-35	8341-8343	at	_
41-36	8344-8345	a	_
41-37	8346-8355	frequency	_
41-38	8356-8358	of	_
41-39	8359-8365	1200Hz	_
41-40	8366-8367	.	_

42-1	8368-8371	The	_
42-2	8372-8379	latency	_
42-3	8380-8387	between	_
42-4	8388-8391	two	_
42-5	8392-8398	target	_
42-6	8399-8404	tones	_
42-7	8405-8411	varied	_
42-8	8412-8419	between	_
42-9	8420-8422	6s	_
42-10	8423-8426	and	_
42-11	8427-8430	15s	_
42-12	8431-8432	,	_
42-13	8433-8441	allowing	_
42-14	8442-8445	for	_
42-15	8446-8459	deconvolution	_
42-16	8460-8462	of	_
42-17	8463-8466	the	_
42-18	8467-8471	BOLD	_
42-19	8472-8478	signal	_
42-20	8479-8480	.	_

43-1	8481-8489	Auditory	_
43-2	8490-8497	stimuli	_
43-3	8498-8502	were	_
43-4	8503-8512	presented	_
43-5	8513-8523	binaurally	_
43-6	8524-8531	through	_
43-7	8532-8542	headphones	_
43-8	8543-8544	.	_

44-1	8545-8550	Prior	_
44-2	8551-8553	to	_
44-3	8554-8557	the	_
44-4	8558-8568	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
44-5	8569-8573	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
44-6	8574-8575	,	_
44-7	8576-8588	participants	_
44-8	8589-8597	adjusted	_
44-9	8598-8603	right	_
44-10	8604-8607	and	_
44-11	8608-8612	left	_
44-12	8613-8616	ear	_
44-13	8617-8624	volumes	_
44-14	8625-8627	to	_
44-15	8628-8629	a	_
44-16	8630-8634	test	_
44-17	8635-8643	stimulus	_
44-18	8644-8646	to	_
44-19	8647-8653	ensure	_
44-20	8654-8657	the	_
44-21	8658-8663	tones	_
44-22	8664-8669	could	_
44-23	8670-8672	be	_
44-24	8673-8678	heard	_
44-25	8679-8683	over	_
44-26	8684-8691	scanner	_
44-27	8692-8697	noise	_
44-28	8698-8699	.	_

45-1	8700-8712	Participants	_
45-2	8713-8717	were	_
45-3	8718-8728	instructed	_
45-4	8729-8731	to	_
45-5	8732-8737	focus	_
45-6	8738-8740	on	_
45-7	8741-8742	a	_
45-8	8743-8748	black	_
45-9	8749-8757	fixation	_
45-10	8758-8763	cross	_
45-11	8764-8773	displayed	_
45-12	8774-8776	on	_
45-13	8777-8778	a	_
45-14	8779-8783	grey	_
45-15	8784-8790	screen	_
45-16	8791-8801	throughout	_
45-17	8802-8805	the	_
45-18	8806-8809	run	_
45-19	8810-8811	,	_
45-20	8812-8815	and	_
45-21	8816-8818	to	_
45-22	8819-8826	respond	_
45-23	8827-8831	with	_
45-24	8832-8833	a	_
45-25	8834-8840	button	_
45-26	8841-8846	press	_
45-27	8847-8851	when	_
45-28	8852-8856	they	_
45-29	8857-8862	heard	_
45-30	8863-8866	the	_
45-31	8867-8873	target	_
45-32	8874-8878	tone	_
45-33	8879-8880	.	_

46-1	8881-8888	Stimuli	_
46-2	8889-8893	were	_
46-3	8894-8903	presented	_
46-4	8904-8909	using	_
46-5	8910-8917	E-Prime	_
46-6	8918-8926	software	_
46-7	8927-8928	(	_
46-8	8929-8933	http	_
46-9	8934-8935	:	_
46-10	8936-8970	//www.pstnet.com/products/e-prime/	_
46-11	8971-8972	)	_
46-12	8973-8974	.	_

47-1	8975-8980	After	_
47-2	8981-8984	the	_
47-3	8985-8995	experiment	_
47-4	8996-8997	,	_
47-5	8998-9006	patients	_
47-6	9007-9011	were	_
47-7	9012-9017	asked	_
47-8	9018-9025	whether	_
47-9	9026-9030	they	_
47-10	9031-9042	experienced	_
47-11	9043-9057	hallucinations	_
47-12	9058-9064	during	_
47-13	9065-9068	the	_
47-14	9069-9077	scanning	_
47-15	9078-9085	session	_
47-16	9086-9087	,	_
47-17	9088-9092	with	_
47-18	9093-9096	one	_
47-19	9097-9104	patient	_
47-20	9105-9114	reporting	_
47-21	9115-9119	AVHs	_
47-22	9120-9121	“	_
47-23	9122-9128	almost	_
47-24	9129-9139	constantly	_
47-25	9140-9141	”	_
47-26	9142-9143	,	_
47-27	9144-9147	one	_
47-28	9148-9149	“	_
47-29	9150-9162	occasionally	_
47-30	9163-9164	”	_
47-31	9165-9166	,	_
47-32	9167-9170	and	_
47-33	9171-9174	one	_
47-34	9175-9184	reporting	_
47-35	9185-9191	visual	_
47-36	9192-9206	hallucinations	_
47-37	9207-9219	occasionally	_
47-38	9220-9221	(	_
47-39	9222-9226	data	_
47-40	9227-9231	were	_
47-41	9232-9239	missing	_
47-42	9240-9243	for	_
47-43	9244-9246	11	_
47-44	9247-9255	subjects	_
47-45	9256-9257	)	_
47-46	9258-9259	.	_

48-1	9260-9265	Image	_
48-2	9266-9277	Acquisition	_
48-3	9278-9281	and	_
48-4	9282-9292	Processing	_
48-5	9293-9300	Imaging	_
48-6	9301-9304	for	_
48-7	9305-9308	the	_
48-8	9309-9317	sentence	_
48-9	9318-9322	task	_
48-10	9323-9327	data	_
48-11	9328-9331	was	_
48-12	9332-9341	performed	_
48-13	9342-9344	at	_
48-14	9345-9348	the	_
48-15	9349-9359	University	_
48-16	9360-9362	of	_
48-17	9363-9370	British	_
48-18	9371-9379	Columbia	_
48-19	9380-9383	MRI	_
48-20	9384-9392	Research	_
48-21	9393-9399	Centre	_
48-22	9400-9405	using	_
48-23	9406-9407	a	_
48-24	9408-9415	Philips	_
48-25	9416-9423	Achieva	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
48-26	9424-9427	3.0	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
48-27	9428-9433	Tesla	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
48-28	9434-9435	(	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
48-29	9436-9437	T	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
48-30	9438-9439	)	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
48-31	9440-9443	MRI	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
48-32	9444-9451	scanner	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
48-33	9452-9456	with	_
48-34	9457-9463	quasar	_
48-35	9464-9468	dual	_
48-36	9469-9478	gradients	_
48-37	9479-9480	(	_
48-38	9481-9488	maximum	_
48-39	9489-9497	gradient	_
48-40	9498-9507	amplitude	_
48-41	9508-9509	,	_
48-42	9510-9516	80mT/m	_
48-43	9517-9518	;	_
48-44	9519-9526	maximum	_
48-45	9527-9531	slew	_
48-46	9532-9536	rate	_
48-47	9537-9538	,	_
48-48	9539-9542	200	_
48-49	9543-9549	mT/m/s	_
48-50	9550-9551	)	_
48-51	9552-9553	.	_

49-1	9554-9557	The	_
49-2	9558-9569	participant	_
49-3	9570-9571	’	_
49-4	9572-9573	s	_
49-5	9574-9578	head	_
49-6	9579-9582	was	_
49-7	9583-9589	firmly	_
49-8	9590-9597	secured	_
49-9	9598-9603	using	_
49-10	9604-9605	a	_
49-11	9606-9616	customized	_
49-12	9617-9621	head	_
49-13	9622-9628	holder	_
49-14	9629-9630	.	_

50-1	9631-9641	Functional	_
50-2	9642-9647	image	_
50-3	9648-9655	volumes	_
50-4	9656-9660	were	_
50-5	9661-9670	collected	_
50-6	9671-9676	using	_
50-7	9677-9678	a	_
50-8	9679-9681	T2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
50-9	9682-9683	*	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
50-10	9684-9693	-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
50-11	9694-9707	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
50-12	9708-9712	spin	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
50-13	9713-9718	pulse	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
50-14	9719-9727	sequence	_
50-15	9728-9732	with	_
50-16	9733-9735	36	_
50-17	9736-9741	axial	_
50-18	9742-9748	slices	_
50-19	9749-9750	;	_
50-20	9751-9764	thickness/gap	_
50-21	9765-9766	,	_
50-22	9767-9770	3/1	_
50-23	9771-9773	mm	_
50-24	9774-9775	;	_
50-25	9776-9782	matrix	_
50-26	9783-9784	,	_
50-27	9785-9790	80×80	_
50-28	9791-9792	;	_
50-29	9793-9803	repetition	_
50-30	9804-9808	time	_
50-31	9809-9810	(	_
50-32	9811-9813	TR	_
50-33	9814-9815	)	_
50-34	9816-9817	,	_
50-35	9818-9822	2500	_
50-36	9823-9825	ms	_
50-37	9826-9827	;	_
50-38	9828-9832	echo	_
50-39	9833-9837	time	_
50-40	9838-9839	(	_
50-41	9840-9842	TE	_
50-42	9843-9844	)	_
50-43	9845-9846	,	_
50-44	9847-9849	30	_
50-45	9850-9852	ms	_
50-46	9853-9854	;	_
50-47	9855-9859	flip	_
50-48	9860-9865	angle	_
50-49	9866-9867	(	_
50-50	9868-9870	FA	_
50-51	9871-9872	)	_
50-52	9873-9874	,	_
50-53	9875-9878	90°	_
50-54	9879-9880	,	_
50-55	9881-9886	field	_
50-56	9887-9889	of	_
50-57	9890-9894	view	_
50-58	9895-9896	(	_
50-59	9897-9900	FOV	_
50-60	9901-9902	)	_
50-61	9903-9904	,	_
50-62	9905-9912	240×240	_
50-63	9913-9915	mm	_
50-64	9916-9917	,	_
50-65	9918-9929	effectively	_
50-66	9930-9938	covering	_
50-67	9939-9942	the	_
50-68	9943-9948	whole	_
50-69	9949-9954	brain	_
50-70	9955-9956	.	_

51-1	9957-9960	352	_
51-2	9961-9967	images	_
51-3	9968-9972	were	_
51-4	9973-9981	acquired	_
51-5	9982-9986	over	_
51-6	9987-9990	two	_
51-7	9991-9995	runs	_
51-8	9996-9998	of	_
51-9	9999-10012	approximately	_
51-10	10013-10014	7	_
51-11	10015-10018	min	_
51-12	10019-10022	and	_
51-13	10023-10025	30	_
51-14	10026-10027	s	_
51-15	10028-10032	each	_
51-16	10033-10034	.	_

52-1	10035-10042	Imaging	_
52-2	10043-10046	for	_
52-3	10047-10050	the	_
52-4	10051-10056	fBIRN	http://maven.renci.org/NeuroBridge/neurobridge#BirchwoodSocialFunctioningScale
52-5	10057-10061	data	_
52-6	10062-10065	was	_
52-7	10066-10075	performed	_
52-8	10076-10078	at	_
52-9	10079-10083	five	_
52-10	10084-10089	sites	_
52-11	10090-10091	(	_
52-12	10092-10095	one	_
52-13	10096-10100	site	_
52-14	10101-10104	was	_
52-15	10105-10113	excluded	_
52-16	10114-10120	during	_
52-17	10121-10128	quality	_
52-18	10129-10136	control	_
52-19	10137-10138	)	_
52-20	10139-10145	across	_
52-21	10146-10149	the	_
52-22	10150-10156	United	_
52-23	10157-10163	States	_
52-24	10164-10166	of	_
52-25	10167-10174	America	_
52-26	10175-10176	,	_
52-27	10177-10180	for	_
52-28	10181-10186	which	_
52-29	10187-10194	imaging	_
52-30	10195-10205	parameters	_
52-31	10206-10210	were	_
52-32	10211-10218	matched	_
52-33	10219-10221	as	_
52-34	10222-10229	closely	_
52-35	10230-10232	as	_
52-36	10233-10241	possible	_
52-37	10242-10247	based	_
52-38	10248-10250	on	_
52-39	10251-10262	preliminary	_
52-40	10263-10270	testing	_
52-41	10271-10272	:	_
52-42	10273-10275	27	_
52-43	10276-10282	slices	_
52-44	10283-10285	if	_
52-45	10286-10294	possible	_
52-46	10295-10296	;	_
52-47	10297-10310	thickness/gap	_
52-48	10311-10312	=	_
52-49	10313-10320	4mm/1mm	_
52-50	10321-10322	;	_
52-51	10323-10329	matrix	_
52-52	10330-10331	=	_
52-53	10332-10337	64×64	_
52-54	10338-10339	;	_
52-55	10340-10350	repetition	_
52-56	10351-10355	time	_
52-57	10356-10357	(	_
52-58	10358-10360	TR	_
52-59	10361-10362	)	_
52-60	10363-10364	=	_
52-61	10365-10369	2000	_
52-62	10370-10372	ms	_
52-63	10373-10374	;	_
52-64	10375-10379	echo	_
52-65	10380-10384	time	_
52-66	10385-10386	(	_
52-67	10387-10389	TE	_
52-68	10390-10391	)	_
52-69	10392-10393	=	_
52-70	10394-10398	30ms	_
52-71	10399-10400	(	_
52-72	10401-10403	3T	_
52-73	10404-10405	)	_
52-74	10406-10411	/40ms	_
52-75	10412-10413	(	_
52-76	10414-10418	1.5T	_
52-77	10419-10420	)	_
52-78	10421-10422	;	_
52-79	10423-10427	flip	_
52-80	10428-10433	angle	_
52-81	10434-10435	(	_
52-82	10436-10438	FA	_
52-83	10439-10440	)	_
52-84	10441-10442	=	_
52-85	10443-10446	90°	_
52-86	10447-10448	;	_
52-87	10449-10454	field	_
52-88	10455-10457	of	_
52-89	10458-10462	view	_
52-90	10463-10464	(	_
52-91	10465-10468	FOV	_
52-92	10469-10470	)	_
52-93	10471-10472	=	_
52-94	10473-10477	22cm	_
52-95	10478-10479	;	_
52-96	10480-10485	voxel	_
52-97	10486-10496	dimensions	_
52-98	10497-10498	=	_
52-99	10499-10505	3.4375	_
52-100	10506-10507	×	_
52-101	10508-10514	3.4375	_
52-102	10515-10516	×	_
52-103	10517-10518	4	_
52-104	10519-10521	mm	_
52-105	10522-10523	)	_
52-106	10524-10525	.	_

53-1	10526-10529	One	_
53-2	10530-10534	site	_
53-3	10535-10536	(	_
53-4	10537-10545	Duke/UNC	_
53-5	10546-10547	)	_
53-6	10548-10556	employed	_
53-7	10557-10558	a	_
53-8	10559-10565	spiral	_
53-9	10566-10570	echo	_
53-10	10571-10579	sequence	_
53-11	10580-10581	,	_
53-12	10582-10587	while	_
53-13	10588-10591	all	_
53-14	10592-10597	other	_
53-15	10598-10603	sites	_
53-16	10604-10608	used	_
53-17	10609-10610	a	_
53-18	10611-10622	single-shot	_
53-19	10623-10626	EPI	_
53-20	10627-10635	sequence	_
53-21	10636-10637	.	_

54-1	10638-10641	140	_
54-2	10642-10649	volumes	_
54-3	10650-10654	were	_
54-4	10655-10664	collected	_
54-5	10665-10667	in	_
54-6	10668-10672	each	_
54-7	10673-10676	run	_
54-8	10677-10684	lasting	_
54-9	10685-10689	280s	_
54-10	10690-10691	.	_

55-1	10692-10702	Functional	_
55-2	10703-10710	volumes	_
55-3	10711-10714	for	_
55-4	10715-10719	both	_
55-5	10720-10728	datasets	_
55-6	10729-10733	were	_
55-7	10734-10747	pre-processed	_
55-8	10748-10753	using	_
55-9	10754-10765	Statistical	_
55-10	10766-10776	Parametric	_
55-11	10777-10784	Mapping	_
55-12	10785-10786	8	_
55-13	10787-10788	(	_
55-14	10789-10793	SPM8	_
55-15	10794-10795	;	_
55-16	10796-10804	Wellcome	_
55-17	10805-10810	Trust	_
55-18	10811-10817	Centre	_
55-19	10818-10821	for	_
55-20	10822-10834	Neuroimaging	_
55-21	10835-10836	,	_
55-22	10837-10839	UK	_
55-23	10840-10841	)	_
55-24	10842-10843	.	_

56-1	10844-10847	For	_
56-2	10848-10852	each	_
56-3	10853-10864	participant	_
56-4	10865-10866	,	_
56-5	10867-10871	each	_
56-6	10872-10882	functional	_
56-7	10883-10886	run	_
56-8	10887-10890	was	_
56-9	10891-10900	realigned	_
56-10	10901-10902	,	_
56-11	10903-10913	normalized	_
56-12	10914-10916	to	_
56-13	10917-10920	the	_
56-14	10921-10929	Montreal	_
56-15	10930-10942	Neurological	_
56-16	10943-10952	Institute	_
56-17	10953-10954	(	_
56-18	10955-10958	MNI	_
56-19	10959-10960	)	_
56-20	10961-10964	EPI	_
56-21	10965-10970	brain	_
56-22	10971-10979	template	_
56-23	10980-10981	(	_
56-24	10982-10987	voxel	_
56-25	10988-10992	size	_
56-26	10993-10994	=	_
56-27	10995-10996	2	_
56-28	10997-11000	mm3	_
56-29	11001-11002	)	_
56-30	11003-11004	,	_
56-31	11005-11008	and	_
56-32	11009-11018	spatially	_
56-33	11019-11027	smoothed	_
56-34	11028-11032	with	_
56-35	11033-11035	an	_
56-36	11036-11039	8mm	_
56-37	11040-11044	full	_
56-38	11045-11050	width	_
56-39	11051-11053	at	_
56-40	11054-11058	half	_
56-41	11059-11066	maximum	_
56-42	11067-11075	Gaussian	_
56-43	11076-11082	filter	_
56-44	11083-11084	.	_

57-1	11085-11094	Following	_
57-2	11095-11108	preprocessing	_
57-3	11109-11110	,	_
57-4	11111-11114	the	_
57-5	11115-11118	SPM	_
57-6	11119-11130	realignment	_
57-7	11131-11141	parameters	_
57-8	11142-11146	were	_
57-9	11147-11155	examined	_
57-10	11156-11157	,	_
57-11	11158-11161	and	_
57-12	11162-11165	any	_
57-13	11166-11170	runs	_
57-14	11171-11180	exceeding	_
57-15	11181-11184	3mm	_
57-16	11185-11196	translation	_
57-17	11197-11199	or	_
57-18	11200-11202	3°	_
57-19	11203-11211	rotation	_
57-20	11212-11216	were	_
57-21	11217-11225	excluded	_
57-22	11226-11230	from	_
57-23	11231-11238	further	_
57-24	11239-11247	analysis	_
57-25	11248-11249	.	_

58-1	11250-11254	This	_
58-2	11255-11258	led	_
58-3	11259-11261	to	_
58-4	11262-11265	the	_
58-5	11266-11273	removal	_
58-6	11274-11276	of	_
58-7	11277-11279	29	_
58-8	11280-11284	runs	_
58-9	11285-11287	in	_
58-10	11288-11291	the	_
58-11	11292-11297	fBIRN	_
58-12	11298-11304	sample	_
58-13	11305-11306	.	_

59-1	11307-11317	Additional	_
59-2	11318-11325	quality	_
59-3	11326-11333	control	_
59-4	11334-11344	procedures	_
59-5	11345-11348	for	_
59-6	11349-11352	the	_
59-7	11353-11358	fBIRN	_
59-8	11359-11365	sample	_
59-9	11366-11374	included	_
59-10	11375-11383	removing	_
59-11	11384-11388	runs	_
59-12	11389-11392	for	_
59-13	11393-11399	images	_
59-14	11400-11404	that	_
59-15	11405-11411	showed	_
59-16	11412-11421	artifacts	_
59-17	11422-11428	and/or	_
59-18	11429-11432	led	_
59-19	11433-11435	to	_
59-20	11436-11442	errors	_
59-21	11443-11449	during	_
59-22	11450-11463	preprocessing	_
59-23	11464-11465	,	_
59-24	11466-11469	and	_
59-25	11470-11473	for	_
59-26	11474-11478	runs	_
59-27	11479-11481	in	_
59-28	11482-11487	which	_
59-29	11488-11493	there	_
59-30	11494-11498	were	_
59-31	11499-11502	few	_
59-32	11503-11512	responses	_
59-33	11513-11515	or	_
59-34	11516-11517	a	_
59-35	11518-11522	high	_
59-36	11523-11528	false	_
59-37	11529-11537	positive	_
59-38	11538-11542	rate	_
59-39	11543-11544	,	_
59-40	11545-11555	suggesting	_
59-41	11556-11568	participants	_
59-42	11569-11573	were	_
59-43	11574-11577	not	_
59-44	11578-11585	engaged	_
59-45	11586-11588	in	_
59-46	11589-11592	the	_
59-47	11593-11597	task	_
59-48	11598-11599	.	_

60-1	11600-11607	Further	_
60-2	11608-11619	information	_
60-3	11620-11622	on	_
60-4	11623-11627	this	_
60-5	11628-11635	quality	_
60-6	11636-11643	control	_
60-7	11644-11647	can	_
60-8	11648-11650	be	_
60-9	11651-11656	found	_
60-10	11657-11659	in	_
60-11	11660-11668	previous	_
60-12	11669-11673	work	_
60-13	11674-11675	.	_

61-1	11676-11680	Data	_
61-2	11681-11689	Analysis	_
61-3	11690-11695	Group	_
61-4	11696-11705	fMRI-CPCA	_
61-5	11706-11710	fMRI	_
61-6	11711-11715	data	_
61-7	11716-11724	analysis	_
61-8	11725-11728	was	_
61-9	11729-11736	carried	_
61-10	11737-11740	out	_
61-11	11741-11746	using	_
61-12	11747-11758	constrained	_
61-13	11759-11768	principal	_
61-14	11769-11778	component	_
61-15	11779-11787	analysis	_
61-16	11788-11791	for	_
61-17	11792-11796	fMRI	_
61-18	11797-11799	to	_
61-19	11800-11807	compare	_
61-20	11808-11814	groups	_
61-21	11815-11816	(	_
61-22	11817-11822	group	_
61-23	11823-11832	fMRI-CPCA	_
61-24	11833-11834	)	_
61-25	11835-11839	with	_
61-26	11840-11850	orthogonal	_
61-27	11851-11859	rotation	_
61-28	11860-11861	(	_
61-29	11862-11863	;	_
61-30	11864-11865	)	_
61-31	11866-11867	.	_

62-1	11868-11871	The	_
62-2	11872-11878	theory	_
62-3	11879-11882	and	_
62-4	11883-11889	proofs	_
62-5	11890-11893	for	_
62-6	11894-11898	CPCA	_
62-7	11899-11902	are	_
62-8	11903-11911	detailed	_
62-9	11912-11914	in	_
62-10	11915-11925	previously	_
62-11	11926-11935	published	_
62-12	11936-11940	work	_
62-13	11941-11942	.	_

63-1	11943-11946	The	_
63-2	11947-11956	fMRI-CPCA	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
63-3	11957-11968	application	_
63-4	11969-11971	is	_
63-5	11972-11981	available	_
63-6	11982-11989	on-line	_
63-7	11990-11991	,	_
63-8	11992-11996	free	_
63-9	11997-11999	of	_
63-10	12000-12006	charge	_
63-11	12007-12008	(	_
63-12	12009-12040	www.nitrc.org/projects/fmricpca	_
63-13	12041-12042	)	_
63-14	12043-12044	.	_

64-1	12045-12054	fMRI-CPCA	_
64-2	12055-12063	computes	_
64-3	12064-12065	(	_
64-4	12066-12069	via	_
64-5	12070-12073	PCA	_
64-6	12074-12075	)	_
64-7	12076-12086	components	_
64-8	12087-12099	representing	_
64-9	12100-12110	functional	_
64-10	12111-12116	brain	_
64-11	12117-12125	networks	_
64-12	12126-12128	on	_
64-13	12129-12141	blood-oxygen	_
64-14	12142-12157	level-dependent	_
64-15	12158-12159	(	_
64-16	12160-12164	BOLD	_
64-17	12165-12166	)	_
64-18	12167-12173	signal	_
64-19	12174-12177	for	_
64-20	12178-12183	which	_
64-21	12184-12192	variance	_
64-22	12193-12196	has	_
64-23	12197-12201	been	_
64-24	12202-12213	constrained	_
64-25	12214-12215	(	_
64-26	12216-12219	via	_
64-27	12220-12232	multivariate	_
64-28	12233-12241	multiple	_
64-29	12242-12252	regression	_
64-30	12253-12254	)	_
64-31	12255-12257	to	_
64-32	12258-12262	that	_
64-33	12263-12274	predictable	_
64-34	12275-12279	from	_
64-35	12280-12284	task	_
64-36	12285-12291	timing	_
64-37	12292-12293	,	_
64-38	12294-12297	and	_
64-39	12298-12306	provides	_
64-40	12307-12311	both	_
64-41	12312-12319	spatial	_
64-42	12320-12321	(	_
64-43	12322-12330	dominant	_
64-44	12331-12336	brain	_
64-45	12337-12344	regions	_
64-46	12345-12346	)	_
64-47	12347-12350	and	_
64-48	12351-12359	temporal	_
64-49	12360-12361	(	_
64-50	12362-12373	hemodynamic	_
64-51	12374-12382	response	_
64-52	12383-12389	shapes	_
64-53	12390-12391	)	_
64-54	12392-12403	information	_
64-55	12404-12407	for	_
64-56	12408-12412	each	_
64-57	12413-12423	task-based	_
64-58	12424-12434	functional	_
64-59	12435-12440	brain	_
64-60	12441-12448	network	_
64-61	12449-12450	.	_

65-1	12451-12455	When	_
65-2	12456-12463	applied	_
65-3	12464-12466	to	_
65-4	12467-12475	multiple	_
65-5	12476-12484	datasets	_
65-6	12485-12486	,	_
65-7	12487-12492	group	_
65-8	12493-12502	fMRI-CPCA	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
65-9	12503-12509	allows	_
65-10	12510-12513	for	_
65-11	12514-12527	visualization	_
65-12	12528-12530	of	_
65-13	12531-12542	task-common	_
65-14	12543-12546	and	_
65-15	12547-12560	task-specific	_
65-16	12561-12569	networks	_
65-17	12570-12571	,	_
65-18	12572-12579	through	_
65-19	12580-12591	observation	_
65-20	12592-12594	of	_
65-21	12595-12602	spatial	_
65-22	12603-12606	and	_
65-23	12607-12615	temporal	_
65-24	12616-12627	replication	_
65-25	12628-12634	across	_
65-26	12635-12640	tasks	_
65-27	12641-12647	within	_
65-28	12648-12652	each	_
65-29	12653-12660	network	_
65-30	12661-12662	.	_

66-1	12663-12668	Group	_
66-2	12669-12678	fMRI-CPCA	_
66-3	12679-12687	involved	_
66-4	12688-12691	the	_
66-5	12692-12703	preparation	_
66-6	12704-12706	of	_
66-7	12707-12710	two	_
66-8	12711-12719	matrices	_
66-9	12720-12721	:	_
66-10	12722-12723	(	_
66-11	12724-12725	1	_
66-12	12726-12727	)	_
66-13	12728-12729	a	_
66-14	12730-12734	data	_
66-15	12735-12741	matrix	_
66-16	12742-12743	(	_
66-17	12744-12745	Z	_
66-18	12746-12747	)	_
66-19	12748-12749	,	_
66-20	12750-12760	containing	_
66-21	12761-12764	the	_
66-22	12765-12769	BOLD	_
66-23	12770-12774	time	_
66-24	12775-12781	series	_
66-25	12782-12784	of	_
66-26	12785-12789	each	_
66-27	12790-12795	voxel	_
66-28	12796-12797	,	_
66-29	12798-12802	with	_
66-30	12803-12806	one	_
66-31	12807-12813	column	_
66-32	12814-12817	per	_
66-33	12818-12823	voxel	_
66-34	12824-12827	and	_
66-35	12828-12831	one	_
66-36	12832-12835	row	_
66-37	12836-12839	per	_
66-38	12840-12845	whole	_
66-39	12846-12851	brain	_
66-40	12852-12856	scan	_
66-41	12857-12858	;	_
66-42	12859-12862	and	_
66-43	12863-12864	(	_
66-44	12865-12866	2	_
66-45	12867-12868	)	_
66-46	12869-12872	the	_
66-47	12873-12879	design	_
66-48	12880-12886	matrix	_
66-49	12887-12888	(	_
66-50	12889-12890	G	_
66-51	12891-12892	)	_
66-52	12893-12894	,	_
66-53	12895-12905	containing	_
66-54	12906-12912	finite	_
66-55	12913-12920	impulse	_
66-56	12921-12929	response	_
66-57	12930-12931	(	_
66-58	12932-12935	FIR	_
66-59	12936-12937	)	_
66-60	12938-12944	models	_
66-61	12945-12947	of	_
66-62	12948-12951	the	_
66-63	12952-12960	expected	_
66-64	12961-12965	BOLD	_
66-65	12966-12974	response	_
66-66	12975-12977	to	_
66-67	12978-12981	the	_
66-68	12982-12988	timing	_
66-69	12989-12995	onsets	_
66-70	12996-12998	of	_
66-71	12999-13007	stimulus	_
66-72	13008-13021	presentations	_
66-73	13022-13023	(	_
66-74	13024-13028	i.e.	_
66-75	13029-13030	,	_
66-76	13031-13039	pictures	_
66-77	13040-13043	for	_
66-78	13044-13047	the	_
66-79	13048-13056	sentence	_
66-80	13057-13061	task	_
66-81	13062-13063	,	_
66-82	13064-13070	target	_
66-83	13071-13076	tones	_
66-84	13077-13080	for	_
66-85	13081-13084	the	_
66-86	13085-13092	oddball	_
66-87	13093-13097	task	_
66-88	13098-13099	)	_
66-89	13100-13101	.	_

67-1	13102-13104	In	_
67-2	13105-13110	order	_
67-3	13111-13113	to	_
67-4	13114-13121	compare	_
67-5	13122-13132	functional	_
67-6	13133-13138	brain	_
67-7	13139-13147	networks	_
67-8	13148-13154	across	_
67-9	13155-13166	experiments	_
67-10	13167-13168	,	_
67-11	13169-13173	data	_
67-12	13174-13178	from	_
67-13	13179-13182	all	_
67-14	13183-13188	tasks	_
67-15	13189-13190	(	_
67-16	13191-13193	SP	_
67-17	13194-13195	,	_
67-18	13196-13199	VTG	_
67-19	13200-13201	,	_
67-20	13202-13204	AO	_
67-21	13205-13206	)	_
67-22	13207-13211	were	_
67-23	13212-13220	included	_
67-24	13221-13223	in	_
67-25	13224-13225	Z	_
67-26	13226-13227	,	_
67-27	13228-13235	leading	_
67-28	13236-13238	to	_
67-29	13239-13240	a	_
67-30	13241-13247	matrix	_
67-31	13248-13250	of	_
67-32	13251-13257	115040	_
67-33	13258-13262	rows	_
67-34	13263-13264	(	_
67-35	13265-13268	158	_
67-36	13269-13277	subjects	_
67-37	13278-13279	×	_
67-38	13280-13282	up	_
67-39	13283-13285	to	_
67-40	13286-13288	11	_
67-41	13289-13293	runs	_
67-42	13294-13295	×	_
67-43	13296-13298	up	_
67-44	13299-13301	to	_
67-45	13302-13305	176	_
67-46	13306-13313	volumes	_
67-47	13314-13315	)	_
67-48	13316-13319	and	_
67-49	13320-13327	585,930	_
67-50	13328-13335	columns	_
67-51	13336-13337	(	_
67-52	13338-13344	voxels	_
67-53	13345-13347	in	_
67-54	13348-13352	2mm3	_
67-55	13353-13363	resolution	_
67-56	13364-13365	)	_
67-57	13366-13367	.	_

68-1	13368-13372	Each	_
68-2	13373-13379	column	_
68-3	13380-13389	contained	_
68-4	13390-13400	normalized	_
68-5	13401-13404	and	_
68-6	13405-13413	smoothed	_
68-7	13414-13425	activations	_
68-8	13426-13430	over	_
68-9	13431-13434	all	_
68-10	13435-13440	scans	_
68-11	13441-13442	,	_
68-12	13443-13447	with	_
68-13	13448-13456	subjects	_
68-14	13457-13458	,	_
68-15	13459-13463	runs	_
68-16	13464-13465	,	_
68-17	13466-13469	and	_
68-18	13470-13475	scans	_
68-19	13476-13483	stacked	_
68-20	13484-13494	vertically	_
68-21	13495-13497	to	_
68-22	13498-13505	produce	_
68-23	13506-13507	Z	_
68-24	13508-13509	.	_

69-1	13510-13512	In	_
69-2	13513-13514	G	_
69-3	13515-13516	,	_
69-4	13517-13518	a	_
69-5	13519-13524	value	_
69-6	13525-13526	1	_
69-7	13527-13530	was	_
69-8	13531-13537	placed	_
69-9	13538-13540	in	_
69-10	13541-13545	rows	_
69-11	13546-13549	for	_
69-12	13550-13555	which	_
69-13	13556-13560	BOLD	_
69-14	13561-13567	signal	_
69-15	13568-13577	amplitude	_
69-16	13578-13581	was	_
69-17	13582-13584	to	_
69-18	13585-13587	be	_
69-19	13588-13597	estimated	_
69-20	13598-13599	,	_
69-21	13600-13603	and	_
69-22	13604-13607	the	_
69-23	13608-13613	value	_
69-24	13614-13615	0	_
69-25	13616-13618	in	_
69-26	13619-13622	all	_
69-27	13623-13628	other	_
69-28	13629-13633	rows	_
69-29	13634-13635	,	_
69-30	13636-13644	creating	_
69-31	13645-13646	“	_
69-32	13647-13651	mini	_
69-33	13652-13658	boxcar	_
69-34	13659-13660	”	_
69-35	13661-13670	functions	_
69-36	13671-13672	.	_

70-1	13673-13676	The	_
70-2	13677-13684	columns	_
70-3	13685-13687	of	_
70-4	13688-13689	G	_
70-5	13690-13694	code	_
70-6	13695-13696	7	_
70-7	13697-13709	poststimulus	_
70-8	13710-13714	time	_
70-9	13715-13721	points	_
70-10	13722-13725	for	_
70-11	13726-13730	each	_
70-12	13731-13740	condition	_
70-13	13741-13742	(	_
70-14	13743-13745	SP	_
70-15	13746-13747	,	_
70-16	13748-13751	VTG	_
70-17	13752-13753	,	_
70-18	13754-13756	AO	_
70-19	13757-13758	)	_
70-20	13759-13762	for	_
70-21	13763-13767	each	_
70-22	13768-13770	of	_
70-23	13771-13774	the	_
70-24	13775-13776	(	_
70-25	13777-13785	combined	_
70-26	13786-13787	)	_
70-27	13788-13791	158	_
70-28	13792-13800	subjects	_
70-29	13801-13802	,	_
70-30	13803-13811	totaling	_
70-31	13812-13816	3318	_
70-32	13817-13824	columns	_
70-33	13825-13826	(	_
70-34	13827-13828	7	_
70-35	13829-13830	×	_
70-36	13831-13832	3	_
70-37	13833-13834	×	_
70-38	13835-13838	158	_
70-39	13839-13840	=	_
70-40	13841-13845	3318	_
70-41	13846-13847	)	_
70-42	13848-13849	.	_

71-1	13850-13855	These	_
71-2	13856-13860	time	_
71-3	13861-13867	points	_
71-4	13868-13875	reflect	_
71-5	13876-13885	different	_
71-6	13886-13898	poststimulus	_
71-7	13899-13903	time	_
71-8	13904-13910	points	_
71-9	13911-13913	in	_
71-10	13914-13918	each	_
71-11	13919-13924	study	_
71-12	13925-13928	due	_
71-13	13929-13931	to	_
71-14	13932-13935	the	_
71-15	13936-13946	difference	_
71-16	13947-13949	in	_
71-17	13950-13952	TR	_
71-18	13953-13959	across	_
71-19	13960-13967	studies	_
71-20	13968-13969	,	_
71-21	13970-13973	and	_
71-22	13974-13977	are	_
71-23	13978-13987	converted	_
71-24	13988-13990	to	_
71-25	13991-13998	seconds	_
71-26	13999-14001	in	_
71-27	14002-14005	the	_
71-28	14006-14013	figures	_
71-29	14014-14017	and	_
71-30	14018-14025	results	_
71-31	14026-14033	section	_
71-32	14034-14036	to	_
71-33	14037-14047	facilitate	_
71-34	14048-14062	interpretation	_
71-35	14063-14064	.	_

72-1	14065-14070	Group	_
72-2	14071-14080	fMRI-CPCA	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
72-3	14081-14089	proceeds	_
72-4	14090-14092	in	_
72-5	14093-14096	two	_
72-6	14097-14102	steps	_
72-7	14103-14104	.	_

73-1	14105-14110	First	_
73-2	14111-14112	,	_
73-3	14113-14116	the	_
73-4	14117-14121	data	_
73-5	14122-14128	matrix	_
73-6	14129-14130	,	_
73-7	14131-14132	Z	_
73-8	14133-14134	,	_
73-9	14135-14137	is	_
73-10	14138-14147	regressed	_
73-11	14148-14152	onto	_
73-12	14153-14156	the	_
73-13	14157-14163	design	_
73-14	14164-14170	matrix	_
73-15	14171-14172	,	_
73-16	14173-14174	G	_
73-17	14175-14176	,	_
73-18	14177-14182	which	_
73-19	14183-14193	partitions	_
73-20	14194-14197	the	_
73-21	14198-14205	overall	_
73-22	14206-14214	variance	_
73-23	14215-14219	into	_
73-24	14220-14229	predicted	_
73-25	14230-14233	and	_
73-26	14234-14242	residual	_
73-27	14243-14249	scores	_
73-28	14250-14251	.	_

74-1	14252-14255	The	_
74-2	14256-14262	matrix	_
74-3	14263-14272	predicted	_
74-4	14273-14279	scores	_
74-5	14280-14281	,	_
74-6	14282-14287	which	_
74-7	14288-14296	reflects	_
74-8	14297-14305	variance	_
74-9	14306-14308	in	_
74-10	14309-14313	BOLD	_
74-11	14314-14320	signal	_
74-12	14321-14325	that	_
74-13	14326-14328	is	_
74-14	14329-14340	predictable	_
74-15	14341-14345	from	_
74-16	14346-14350	task	_
74-17	14351-14357	timing	_
74-18	14358-14359	,	_
74-19	14360-14362	is	_
74-20	14363-14367	then	_
74-21	14368-14377	submitted	_
74-22	14378-14380	to	_
74-23	14381-14382	a	_
74-24	14383-14392	principal	_
74-25	14393-14402	component	_
74-26	14403-14411	analysis	_
74-27	14412-14413	(	_
74-28	14414-14417	PCA	_
74-29	14418-14419	)	_
74-30	14420-14421	,	_
74-31	14422-14431	resulting	_
74-32	14432-14434	in	_
74-33	14435-14448	task-specific	_
74-34	14449-14459	functional	_
74-35	14460-14465	brain	_
74-36	14466-14474	networks	_
74-37	14475-14476	.	_

75-1	14477-14485	Relation	_
75-2	14486-14488	to	_
75-3	14489-14501	Experimental	_
75-4	14502-14512	Conditions	_
75-5	14513-14518	Group	_
75-6	14519-14528	fMRI-CPCA	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
75-7	14529-14537	produces	_
75-8	14538-14547	predictor	_
75-9	14548-14555	weights	_
75-10	14556-14559	for	_
75-11	14560-14564	each	_
75-12	14565-14576	combination	_
75-13	14577-14579	of	_
75-14	14580-14587	subject	_
75-15	14588-14589	,	_
75-16	14590-14594	task	_
75-17	14595-14604	condition	_
75-18	14605-14606	,	_
75-19	14607-14610	and	_
75-20	14611-14623	poststimulus	_
75-21	14624-14628	time	_
75-22	14629-14630	.	_

76-1	14631-14636	These	_
76-2	14637-14646	predictor	_
76-3	14647-14654	weights	_
76-4	14655-14656	,	_
76-5	14657-14662	which	_
76-6	14663-14670	provide	_
76-7	14671-14680	estimates	_
76-8	14681-14683	of	_
76-9	14684-14687	the	_
76-10	14688-14698	engagement	_
76-11	14699-14701	of	_
76-12	14702-14712	functional	_
76-13	14713-14721	networks	_
76-14	14722-14723	,	_
76-15	14724-14727	can	_
76-16	14728-14730	be	_
76-17	14731-14739	analyzed	_
76-18	14740-14753	statistically	_
76-19	14754-14756	to	_
76-20	14757-14766	determine	_
76-21	14767-14774	whether	_
76-22	14775-14777	or	_
76-23	14778-14781	not	_
76-24	14782-14786	they	_
76-25	14787-14794	reflect	_
76-26	14795-14803	reliable	_
76-27	14804-14807	and	_
76-28	14808-14820	biologically	_
76-29	14821-14830	plausible	_
76-30	14831-14834	HDR	_
76-31	14835-14841	shapes	_
76-32	14842-14843	,	_
76-33	14844-14847	and	_
76-34	14848-14855	whether	_
76-35	14856-14867	differences	_
76-36	14868-14875	between	_
76-37	14876-14882	groups	_
76-38	14883-14889	and/or	_
76-39	14890-14894	task	_
76-40	14895-14905	conditions	_
76-41	14906-14911	exist	_
76-42	14912-14918	within	_
76-43	14919-14923	each	_
76-44	14924-14931	network	_
76-45	14932-14933	.	_

77-1	14934-14939	These	_
77-2	14940-14948	analyses	_
77-3	14949-14953	were	_
77-4	14954-14961	carried	_
77-5	14962-14965	out	_
77-6	14966-14969	for	_
77-7	14970-14974	each	_
77-8	14975-14979	task	_
77-9	14980-14989	condition	_
77-10	14990-15000	separately	_
77-11	15001-15003	as	_
77-12	15004-15009	three	_
77-13	15010-15011	3	_
77-14	15012-15013	×	_
77-15	15014-15015	7	_
77-16	15016-15017	×	_
77-17	15018-15019	3	_
77-18	15020-15031	mixed-model	_
77-19	15032-15038	ANOVAs	_
77-20	15039-15040	(	_
77-21	15041-15044	one	_
77-22	15045-15049	each	_
77-23	15050-15053	for	_
77-24	15054-15056	SP	_
77-25	15057-15058	,	_
77-26	15059-15062	VTG	_
77-27	15063-15064	,	_
77-28	15065-15068	and	_
77-29	15069-15071	AO	_
77-30	15072-15073	)	_
77-31	15074-15075	,	_
77-32	15076-15080	with	_
77-33	15081-15084	the	_
77-34	15085-15100	within-subjects	_
77-35	15101-15108	factors	_
77-36	15109-15111	of	_
77-37	15112-15121	Component	_
77-38	15122-15123	(	_
77-39	15124-15125	3	_
77-40	15126-15136	components	_
77-41	15137-15141	were	_
77-42	15142-15151	extracted	_
77-43	15152-15153	)	_
77-44	15154-15157	and	_
77-45	15158-15170	Poststimulus	_
77-46	15171-15175	Time	_
77-47	15176-15177	(	_
77-48	15178-15179	7	_
77-49	15180-15185	whole	_
77-50	15186-15191	brain	_
77-51	15192-15197	scans	_
77-52	15198-15203	after	_
77-53	15204-15212	stimulus	_
77-54	15213-15218	onset	_
77-55	15219-15220	)	_
77-56	15221-15222	,	_
77-57	15223-15226	and	_
77-58	15227-15230	the	_
77-59	15231-15247	between-subjects	_
77-60	15248-15254	factor	_
77-61	15255-15257	of	_
77-62	15258-15263	Group	_
77-63	15264-15265	(	_
77-64	15266-15273	control	_
77-65	15274-15275	,	_
77-66	15276-15283	non-AVH	_
77-67	15284-15285	,	_
77-68	15286-15289	AVH	_
77-69	15290-15291	)	_
77-70	15292-15293	.	_

78-1	15294-15305	Significant	_
78-2	15306-15315	three-way	_
78-3	15316-15328	interactions	_
78-4	15329-15333	were	_
78-5	15334-15342	followed	_
78-6	15343-15345	up	_
78-7	15346-15350	with	_
78-8	15351-15359	separate	_
78-9	15360-15361	7	_
78-10	15362-15363	×	_
78-11	15364-15365	3	_
78-12	15366-15372	ANOVAs	_
78-13	15373-15376	for	_
78-14	15377-15381	each	_
78-15	15382-15391	component	_
78-16	15392-15393	,	_
78-17	15394-15397	and	_
78-18	15398-15409	significant	_
78-19	15410-15417	two-way	_
78-20	15418-15430	interactions	_
78-21	15431-15435	were	_
78-22	15436-15444	followed	_
78-23	15445-15447	up	_
78-24	15448-15452	with	_
78-25	15453-15459	simple	_
78-26	15460-15469	contrasts	_
78-27	15470-15479	comparing	_
78-28	15480-15484	each	_
78-29	15485-15490	Group	_
78-30	15491-15495	pair	_
78-31	15496-15498	at	_
78-32	15499-15503	each	_
78-33	15504-15509	level	_
78-34	15510-15512	of	_
78-35	15513-15525	Poststimulus	_
78-36	15526-15530	Time	_
78-37	15531-15532	.	_

79-1	15533-15538	Tests	_
79-2	15539-15541	of	_
79-3	15542-15552	sphericity	_
79-4	15553-15557	were	_
79-5	15558-15565	carried	_
79-6	15566-15569	out	_
79-7	15570-15571	,	_
79-8	15572-15575	and	_
79-9	15576-15594	Greenhouse-Geisser	_
79-10	15595-15605	adjustment	_
79-11	15606-15608	in	_
79-12	15609-15616	degrees	_
79-13	15617-15619	of	_
79-14	15620-15627	freedom	_
79-15	15628-15631	for	_
79-16	15632-15635	any	_
79-17	15636-15644	analyses	_
79-18	15645-15647	in	_
79-19	15648-15653	which	_
79-20	15654-15657	the	_
79-21	15658-15668	assumption	_
79-22	15669-15672	was	_
79-23	15673-15681	violated	_
79-24	15682-15685	did	_
79-25	15686-15689	not	_
79-26	15690-15696	affect	_
79-27	15697-15711	interpretation	_
79-28	15712-15714	of	_
79-29	15715-15718	the	_
79-30	15719-15726	results	_
79-31	15727-15728	;	_
79-32	15729-15738	therefore	_
79-33	15739-15740	,	_
79-34	15741-15744	the	_
79-35	15745-15753	original	_
79-36	15754-15761	degrees	_
79-37	15762-15764	of	_
79-38	15765-15769	free	_
79-39	15770-15773	are	_
79-40	15774-15782	reported	_
79-41	15783-15788	below	_
79-42	15789-15790	.	_

80-1	15791-15797	Effect	_
80-2	15798-15803	sizes	_
80-3	15804-15805	(	_
80-4	15806-15813	partial	_
80-5	15814-15817	eta	_
80-6	15818-15825	squared	_
80-7	15826-15827	,	_
80-8	15828-15831	η2p	_
80-9	15832-15833	)	_
80-10	15834-15837	are	_
80-11	15838-15847	displayed	_
80-12	15848-15849	.	_

